Diagnosis and Treatment of Heart Failure

Diagnosis

• The European Society of Cardiology recommends diagnosing heart failure through clinical assessment combined with echocardiography to measure left ventricular ejection fraction (LVEF), and use natriuretic peptides (BNP or NT-proBNP) as an exclusion test due to their high negative predictive value 1
• Identify key symptoms, such as dyspnea on exertion, fatigue, and signs of fluid retention, in patients with suspected heart failure, as recommended by the European Journal of Heart Failure 2, 1
• Classify heart failure by LVEF using echocardiography, with HFrEF (LVEF ≤40%), HFmrEF (LVEF 40-49%), or HFpEF (LVEF ≥50%), according to Praxis Medical Insights 3, 1
• Assess functional severity using NYHA classification (Class II-IV) to guide treatment intensity, as suggested by Praxis Medical Insights 3
• Transthoracic echocardiogram is mandatory to establish diagnosis and determine ejection fraction category, as recommended by Praxis Medical Insights 1
• Natriuretic peptides serve as excellent rule-out tests when negative, avoiding unnecessary further workup, according to Praxis Medical Insights 1
• Evaluate for precipitating factors, such as acute coronary syndrome, arrhythmias, medication non-adherence, or infection, as recommended by Praxis Medical Insights 3

Treatment

• The European Journal of Heart Failure recommends that all patients with HFrEF must receive triple therapy: ACE inhibitors (or ARBs if intolerant), beta-blockers, and diuretics, with aldosterone antagonists added for NYHA Class III-IV disease 2, 1, 3
• Start ACE inhibitors immediately as first-line therapy to reduce mortality and hospitalizations, as recommended by the European Journal of Heart Failure 2, 1, 3
• Initiate beta-blockers in all stable NYHA Class II-IV patients already on ACE inhibitors and diuretics to improve survival, according to the European Journal of Heart Failure 2, 1, 3
• Diuretics are essential for all patients with fluid overload to rapidly improve dyspnea and exercise tolerance, as recommended by the European Journal of Heart Failure 2, 3, 4
• Add spironolactone for NYHA Class III-IV patients on ACE inhibitors and diuretics to improve survival and reduce morbidity, as suggested by the European Journal of Heart Failure 2, 1
• Consider digoxin for symptomatic improvement, especially with atrial fibrillation, though mortality benefit is unproven, according to the European Journal of Heart Failure 2, 5
• Rate control is mandatory in permanent atrial fibrillation, with digoxin as first choice for symptomatic patients, as recommended by the European Journal of Heart Failure 6, 5
• Optimize beta-blocker dose, consider coronary revascularization, add long-acting nitrates, then second-generation dihydropyridines if unsuccessful for concomitant angina, according to the European Journal of Heart Failure 6, 5
• Amiodarone is the preferred agent for severe, symptomatic, sustained ventricular tachycardias, as recommended by the European Journal of Heart Failure 6, 5

Non-Pharmacological Management

• Explain heart failure pathophysiology, symptom recognition, and when to seek help, as recommended by the European Journal of Heart Failure 2, 3
• Teach daily self-weighing and report weight gain >2 kg in 3 days, according to the European Journal of Heart Failure 2, 3
• Emphasize medication adherence to both pharmacological and lifestyle prescriptions, as suggested by the European Journal of Heart Failure 2, 3
• Smoking cessation is mandatory, with nicotine replacement acceptable, according to the European Journal of Heart Failure 2, 3
• Regular exercise is recommended for stable NYHA Class II-III patients to prevent muscle deconditioning and improve quality of life, as recommended by the European Journal of Heart Failure 2, 3
• Control sodium intake in severe heart failure, avoid excessive fluid intake, and limit alcohol consumption, as suggested by the European Journal of Heart Failure 2, 3
• Comprehensive disease management programs improve quality of life, reduce readmissions, and decrease costs, according to the European Journal of Heart Failure 6, 5
• Schedule early follow-up within 7 days of hospital discharge, as recommended by Praxis Medical Insights 3
• Refer high-risk patients to specialized heart failure programs, according to Praxis Medical Insights 3

Common Pitfalls to Avoid

• Inadequate diuresis in volume-overloaded patients leads to persistent symptoms, as noted by Praxis Medical Insights 3
• Failure to uptitrate medications to target doses proven in clinical trials reduces survival benefit, according to Praxis Medical Insights 3
• Neglecting patient education increases readmission rates, as suggested by Praxis Medical Insights 3
• Using NSAIDs or COX-2 inhibitors worsens heart failure and interferes with ACE inhibitor efficacy, according to the European Journal of Heart Failure 2, 4
• Excessive diuresis before ACE inhibitor initiation increases hypotension risk, as recommended by the European Journal of Heart Failure 2
• Starting potassium-sparing diuretics during ACE inhibitor initiation risks dangerous hyperkalemia, according to the European Journal of Heart Failure 2

Heart Failure Management

Pharmacological Therapy

• The European Society of Cardiology recommends that patients with heart failure with reduced ejection fraction (HFrEF) should be treated with a quadruple therapy consisting of an ACE inhibitor or ARNI, beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor, along with diuretics for the management of systemic and pulmonary congestion 7
• ACE inhibitors are the first-line therapy for all patients with left ventricular systolic dysfunction, reducing mortality and hospitalizations by 10-40% depending on severity 7
• Beta-blockers (such as bisoprolol, carvedilol, or metoprolol succinate) should be initiated in all stable patients with NYHA class II-IV, reducing mortality by 35% and sudden death by 40% 7
• Mineralocorticoid receptor antagonists (such as spironolactone) are mandatory when left ventricular ejection fraction (LVEF) is <35% or symptoms persist despite ACE inhibitor and beta-blocker therapy 7

Management of Comorbidities

• For patients with concomitant atrial fibrillation, frequency control is mandatory, and digoxin is the first choice for symptomatic patients 8, 9, 10, 11
• For patients with concomitant angina or hypertension, optimize existing therapy, consider revascularization, and add long-acting nitrates or dihydropyridines as needed 8, 9, 10, 11

Device Therapy

• An implantable cardioverter-defibrillator (ICD) is recommended for symptomatic heart failure (NYHA class II-III) with LVEF ≤35% despite ≥3 months of optimal medical therapy, and not within 40 days of myocardial infarction 7

Non-Pharmacological Management

• Patient education on heart failure pathophysiology, symptom recognition, and when to seek help is essential 8, 9, 10, 11
• Daily weight monitoring and reporting weight gain >2 kg in 3 days is recommended 8, 9, 10, 11
• Comprehensive management programs, including non-pharmacological interventions, are useful for improving quality of life, reducing readmission, and decreasing costs 8, 9, 10, 11